Loading…
Xtl Biopharmaceuticals Ltd
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in XTLB.
▼ -85.6% over 5Y.
today you would have $125.58▼ -87.4%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $2.32 | $8.12 | $4.04 | $4.84 | |
| P/B | 991.6x | — | 1316.8x | 991.6x | 659.5x |
| EPS | — | -$0.80 | -$1.20 | -$0.80 | |
| ROE | -33.71% | — | -18.90% | -80.27% | -33.71% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ENVBEnveric Biosciences, Inc. | $1.37 | — | 0.3x | — | -170.04% | $6.13M |
| ACXPAcurx Pharmaceuticals, Inc. | $1.44 | — | 0.8x | — | -128.11% | $6.19M |
| GELSGelteq Ltd | $0.56 | — | 0.6x | — | -42.93% | $5.95M |
| SNOASonoma Pharmaceuticals, Inc. | $1.31 |
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Herzliya, Israel.
Company description provided by Yahoo Finance.
| — |
| 0.8x |
| — |
| -42.52% |
| $6.27M |
| HCWBHCW Biologics Inc. | $3.43 | — | 0.7x | — | -151.36% | $6.3M |
| ZCMDZhongchao Inc. | $0.92 | — | 0.1x | — | -24.88% | $5.69M |